From 1 May, a validation was placed on the High-Tech Hub which requires the status of a previous order to be updated prior to commencing a new order for Managed Access Protocol High-Tech medicines including cystic fibrosis drugs (Kalydeco, Orkambi, Kaftrio & Symkevi). You can read our previous communication on this topic here.
From 11 June 2024 this validation will be extended to include all cystic fibrosis medicines on the High-Tech Hub. The core list of cystic fibrosis approved medicines can be found here.
It is expected this validation will be rolled out across all High-Tech Hub drugs over the coming months.
